Publicité
Publicité

SBFM

SBFM logo

Sunshine Biopharma Inc.

1.34
USD
Sponsorisé
-0.03
-2.19%
09 janv., 15:59 UTC -5
Fermé
exchange

Après-marché

1.27

-0.07
-4.85%

SBFM Rapports sur les bénéfices

Ratio de surprise positive

SBFM a dépassé 1 des 8 dernières estimations.

13%

Prochain rapport

Date du prochain rapport
30 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
$10.20M
/
-$0.27
Variation implicite de Q3 25 (Revenue/ EPS)
+8.31%
/
+42.11%
Variation implicite de Q4 24 (Revenue/ EPS)
+6.31%
/
-73.00%

Sunshine Biopharma Inc. earnings per share and revenue

On 13 nov. 2025, SBFM reported earnings of -0.19 USD per share (EPS) for Q3 25, missing the estimate of -0.13 USD, resulting in a -43.29% surprise. Revenue reached 9.42 million, compared to an expected 11.32 million, with a -16.82% difference. The market reacted with a -2.40% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analystes forecast an EPS of -0.27 USD, with revenue projected to reach 10.20 million USD, implying an hausse of 42.11% EPS, and hausse of 8.31% in Revenue from the last quarter.
FAQ
For Q3 2025, Sunshine Biopharma Inc. reported EPS of -$0.19, missing estimates by -43.29%, and revenue of $9.42M, -16.82% below expectations.
The stock price moved down -2.4%, changed from $1.67 before the earnings release to $1.63 the day after.
The next earning report is scheduled for 30 mars 2026.
Based on 3 analystes, Sunshine Biopharma Inc. is expected to report EPS of -$0.27 and revenue of $10.20M for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité